



Merrimack
Investor Relations Department
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: MACK


| | |
|---------------|----------------------------|
| Last Trade: | 3.54 |
| Trade Time: | 4:00 PM ET May 23, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 2.83 - 7.14 |
| Volume | 41 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of our product candidates, including three in clinical studies and several others in preclinical development, fit into our three-pronged strategy of 1) understanding the biological problems we are trying to solve, 2) designing specific solution... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 10, 2017*
[Merrimack Reports First Quarter 2017 Financial Results](#)
- May 2, 2017*
[Merrimack Announces Timing of First Quarter 2017 Investor Conference Call](#)
- Apr 17, 2017*
[Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research](#)
- Apr 5, 2017*
[Merrimack Declares \\$140M Special Dividend in Connection with Recently Completed Asset Sale](#)
- Apr 3, 2017*
[Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310](#)

Financials [\[View all \]](#)

- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)